We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The AAPS National Biotechnology Conference is just a week away. West is looking forward to attending this conference in San Diego, CA on May 21-23. This year’s scientific symposia look to be fascinating!
AAPS has chosen a variety of hot topics for the conference, including
If you’re attending, we hope to see you there! In the meantime, tell us what you’re looking forward to!
West’s Paul Cummings, Regional Director, Analytical Services, will present “Container Closure Integrity Testing of Glass and Polymer Containers from Ambient Temperature to -80°C” at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition on November 10-14, 2013, in San Antonio, Texas.
Quality. Technology. Trends in manufacturing. Injection systems. Primary containers. Global market trends. What does each of these areas have in common? Over the past decade tremendous progress has been made in drug delivery, but challenges continue.
The West without Borders charity fundraising initiative had a terrific year in 2011. West employees around the globe contributed more than $210,000 to aid local charities. To date, the charity campaign has raised more than $1 million since its inception in 2004. The 2011 campaign focused on local charities selected by the employees in West’s global facilities
West's Applied Research Team will be presenting two scientific posters at the upcoming International Society for Cell and Gene Therapy 2021 New Orleans Annual Meeting taking place online May 26 – 28, 2021.
The United States Pharmacopeia (USP) requirements for elastomeric components of container closure systems used for parenteral products are changing. The scope of <em>USP <382> Elastomeric Component Functional Suitability in Parenteral Product Packaging/Delivery Systems</em><sup>i </sup> introduces a paradigm shift away from testing elastomeric components individually by the supplier, as was done historically under <em>USP <381> Elastomeric Components in Injectable Pharmaceutical Production Packaging/Delivery Systems</em><sup>ii</sup>, to a holistic evaluation of these components when assembled into drug product packaging and delivery systems. In addition, the testing is performed on the final packaging/delivery system as produced by the drug manufacturer, using product-filled systems or systems filled with a suitable proxy, where applicable. As such, the elastomeric component supplier cannot perform USP <382> testing without knowledge of the specific drug product/proxy or the complete packaging system that the drug manufacturer plans to use. Therefore, the responsibility for USP <382> testing shifts from the elastomeric component supplier to the drug manufacturer.
English
Chinese
